Filtered By:
Management: Electronic Health Records (EHR)
Countries: UK Health

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 6 results found since Jan 2013.

Incidence of neurodegenerative and cerebrovascular diseases associated with antihypertensive drug classes.
Authors: Harrison PJ, Colbourne L, Luciano S Abstract Antihypertensive drugs (AHTs) are associated with lowered risks of neurodegenerative diseases and stroke. However, the relative risks associated with different AHT classes are unclear. Using an electronic health record network with 34 million eligible patients, we compared rates of these disorders over a 2-year period, in propensity score-matched cohorts of people taking calcium channel blockers (CCBs) compared with those taking other AHT classes. CCBs were associated with a higher incidence of all disorders compared with renin-angiotensin system agents, and a h...
Source: The British Journal of Psychiatry for Mental Science - January 9, 2021 Category: Psychiatry Tags: Br J Psychiatry Source Type: research

COVID-19 Can Increase Risk of Psychiatric Disorders for Up to Two Years
The increased risk of depression and anxiety that patients experience after developing COVID-19 typically subsides within two months, according to astudy published yesterday inThe Lancet Psychiatry. However, patients may have an elevated risk for developing other psychiatric and neurological conditions, such as psychosis, brain fog, and seizures, for up to two years after their infections.“The results have important implications for patients and health services as it suggests new cases of neurological conditions linked to COVID-19 infection are likely to occur for a considerable time after the pandemic has subsided,” s...
Source: Psychiatr News - August 18, 2022 Category: Psychiatry Tags: adults anxiety brain fog children COVID-19 delta dementia depression older adults omicron psychotic disorder seizures The Lancet Psychiatry Source Type: research

Active Post-Licensure Safety Surveillance for Recombinant Zoster Vaccine Using Electronic Health Record Data
Am J Epidemiol. 2022 Oct 4:kwac170. doi: 10.1093/aje/kwac170. Online ahead of print.ABSTRACTRecombinant zoster vaccine (RZV) (Shingrix; GlaxoSmithKline, Brentford, United Kingdom) is an adjuvanted glycoprotein vaccine that was licensed in 2017 to prevent herpes zoster and its complications in older adults. In this prospective, post-licensure Vaccine Safety Datalink (VSD) study using electronic health records, we sequentially monitored a real-world population of adults aged 50 years and older who received care at multiple VSD health systems in the United States to identify potential increased risks of 10 pre-specified prior...
Source: Herpes - October 4, 2022 Category: Infectious Diseases Authors: Jennifer C Nelson Ernesto Ulloa-P érez Onchee Yu Andrea J Cook Michael L Jackson Edward A Belongia Matthew F Daley Rafael Harpaz Elyse O Kharbanda Nicola P Klein Allison L Naleway Hung-Fu Tseng Eric S Weintraub Jonathan Duffy W Katherine Yih Lisa A Jacks Source Type: research